Growth factors during HCV therapy may be "cost-effective", but are they "effective"?
Muir
Andrew J
AJ
McHutchison
John G
JG
D000465:Algorithms; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000627:therapeutic use; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000191:economics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
D000998:Antiviral Agents; D036341:Intercellular Signaling Peptides and Proteins; D004921:Erythropoietin; D012254:Ribavirin